Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C

Area of Science:

• Hepatology and viral gastroenterology
• Clinical research on chronic liver disease progression
• Epidemiology of liver fibrosis

Background:

• Previous studies indicated slower liver fibrosis progression in African Americans (AAs) compared to Caucasian Americans (CAs) with chronic Hepatitis C Virus (HCV) infection.
• Understanding racial differences in fibrosis progression is crucial for personalized treatment strategies.

Purpose of the Study:

• To evaluate and compare the rate of liver fibrosis progression between African American and Caucasian American adults with untreated chronic HCV genotype 1 infection.
• To identify factors associated with liver fibrosis progression in this cohort.

Main Methods:

• A multi-state Markov model was employed to analyze fibrosis progression in a cohort of 143 AA and 157 CA adults.
• Duration of infection was imputed for subjects with a history of injection drug use.
• Biopsy adequacy, age at infection, steatosis, ALT level, and necroinflammatory score were considered.

Main Results:

• The distribution of Ishak fibrosis stages was similar between AAs and CAs.
• AAs showed a 10% lower rate of fibrosis progression than CAs, though this difference was not statistically significant (HR, 0.90; 95% CI, 0.72-1.12).
• The estimated median time to cirrhosis was 79 years overall, with variations between racial groups.

Conclusions:

• Liver fibrosis progression rates were slow in the studied cohort.
• There were no substantial differences in fibrosis progression rates observed between African Americans and Caucasian Americans with chronic HCV infection.